Dr. Kumar Sharma, M.D
Nephrology (Kidney) (Nephrology Physician)
- Medicare participating
At a glance
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 73
Licensed in Texas since 2018, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
TX license R8101 (first issued 2018; active) -
Internal Medicine Physician
TX license R8101 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University Health System San Antonio, TX
- Ut Health San Antonio Multispecialty & Research Ho San Antonio, TX
Medical groups
- University of Texas Health Science Center at San Antonio (1,297 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 73
- Services billed
- 173
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 84 | 50 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 26 | 16 |
| New patient office or other outpatient visit, 45-59 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Losartan Potassium Other prescribers in San Antonio, TX | 91 |
| Farxiga (dapagliflozin propanediol) Other prescribers in San Antonio, TX | 71 |
| Furosemide Other prescribers in San Antonio, TX | 29 |
| Jardiance (empagliflozin) Other prescribers in San Antonio, TX | 19 |
| Allopurinol Other prescribers in San Antonio, TX | 17 |
| Amlodipine Besylate Other prescribers in San Antonio, TX | 13 |
| Torsemide Other prescribers in San Antonio, TX | 13 |
| Calcitriol Other prescribers in San Antonio, TX | 12 |
| Hydrochlorothiazide Other prescribers in San Antonio, TX | 12 |
| Carvedilol Other prescribers in San Antonio, TX | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $33.00 in total to this clinician.
| Calliditas Therapeutics US Inc. | $33.00 |
|---|
| Food and Beverage | $33.00 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $11,065 in research payments for these studies, mostly to the institutions running them.
- Trial of Sibeprenlimab in the Treatment of A Nephropathy (IgAN)
Otsuka Pharmaceutical Development & Commercialization, Inc. · Active, not recruiting · NCT05248646
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.